Pay in 4 interest-free payments of $7.20 Learn more
Ships within 48 hours · Estimated delivery Aug 25 - Aug 30
Body composition is a primary consideration
A combination of limited access and high popularity drives the expense
It is a triple receptor agonist, meaning it targets three appetite-regulating hormones in the body: GLP-1 (glucagon-like peptide-1), GIP (glucose-dependent insulinotropic polypeptide), and glucagon
Pfizer, after discontinuing its initial danuglipron candidate due to safety concerns in April 2025, re-entered the race through a $10 billion acquisition of clinical-stage biotech Metsera in November 2025, securing a next-generation obesity pipeline [43]
glutathione handles the cleanup
published third-party studies after GLP-1 withdrawal alone have shown ~15% weight regain at similar time points 33% of patients continued to lose further weight one year after discontinuing a GLP-1 Next anticipated Revita clinical data readouts are one-year randomized data from the REMAIN-1 Midpoint Cohort in Q3 2026 and topline six-month randomized data from the REMAIN-1 Pivotal Cohort in early Q4 2026 BURLINGTON, Mass., June 04, 2026 (GLOBE NEWSWIRE) -- Fractyl Health, Inc
US$ 28.84
US$ 27.55
US$ 20.72
